First Affiliated Hospital, Sun Yat-sen University

This study tested a three-part treatment for people with colorectal cancer that spread to the liver and stopped responding to standard therapies. The treatment combined targeted chemotherapy beads injected into the liver, chemotherapy infusion into the liver artery, and a targete…

This study looked at whether a combination of two pain medicines (hydromorphone and flurbiprofen) given through a vein can better control pain after a liver cancer treatment called TACE. 129 patients with intermediate-to-advanced liver cancer took part. The goal was to see if thi…

This study looked at 328 people with intermediate or high-risk gastrointestinal stromal tumors (GIST) who took imatinib after surgery. The goal was to find the best dose range that prevents the tumor from coming back while keeping side effects low. Researchers measured drug level…

This study looked at 324 liver cancer patients to see if CT scan features could predict who would benefit from adding a targeted drug to standard chemo-embolization therapy. The goal was to improve treatment decisions by identifying patients most likely to respond. The study did …

This study looked at whether MRI scans and computer analysis could help predict how long people with a type of liver cancer (intrahepatic cholangiocarcinoma) would live after surgery. Researchers measured tumor features like fibrosis and a protein called α-SMA. 169 patients were …

This study looked at 151 liver cancer patients whose tumors had spread into the bile ducts. Researchers developed a computer model to identify which patients would benefit most from surgery. Following the model's advice was linked to better long-term survival.

This study looked at medical scans from 3,000 liver cancer patients to see if artificial intelligence could predict who would benefit more from one of two standard treatments: TACE or HAIC. Researchers used a computer model to group patients by tumor features seen on scans. The g…